The Role of Antithrombotic Therapy in Heart Failure

Author(s): Christina Chrysohoou, Nikolaos Magkas*, Christos-Konstantinos Antoniou, Panagiota Manolakou, Aggeliki Laina, Dimitrios Tousoulis

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 23 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Heart failure is a major contributor to global morbidity and mortality burden affecting approximately 1-2% of adults in developed countries, mounting to over 10% in individuals aged >70 years old. Heart failure is characterized by a prothrombotic state and increased rates of stroke and thromboembolism have been reported in heart failure patients compared with the general population. However, the impact of antithrombotic therapy on heart failure remains controversial. Administration of antiplatelet or anticoagulant therapy is the obvious (and well-established) choice in heart failure patients with cardiovascular comorbidity that necessitates their use, such as coronary artery disease or atrial fibrillation. In contrast, antithrombotic therapy has not demonstrated any clear benefit when administered for heart failure per se, i.e. with heart failure being the sole indication. Randomized studies have reported decreased stroke rates with warfarin use in patients with heart failure with reduced left ventricular ejection fraction, but at the expense of excessive bleeding. Non-vitamin K oral anticoagulants have shown a better safety profile in heart failure patients with atrial fibrillation compared with warfarin, however, current evidence about their role in heart failure with sinus rhythm is inconclusive and further research is needed. In the present review, we discuss the role of antithrombotic therapy in heart failure (beyond coronary artery disease), aiming to summarize evidence regarding the thrombotic risk and the role of antiplatelet and anticoagulant agents in patients with heart failure.

Keywords: heart failure, stroke, thromboembolism, atrial fibrillation, antiplatelet agents, vitamin K antagonists, non-vitamin K oral anticoagulants.

[1]
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129-200.
[http://dx.doi.org/10.1093/eurheartj/ehw128] [PMID: 27206819]
[2]
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation 2013; 127(1): e6-245.
[http://dx.doi.org/10.1161/CIR.0b013e31828124ad] [PMID: 23239837]
[3]
Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev 2017; 3(1): 7-11.
[http://dx.doi.org/10.15420/cfr.2016:25:2] [PMID: 28785469]
[4]
Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63(12): 1123-33.
[http://dx.doi.org/10.1016/j.jacc.2013.11.053] [PMID: 24491689]
[5]
Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39(9): 763-816.
[http://dx.doi.org/10.1093/eurheartj/ehx095] [PMID: 28886620]
[6]
Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38): 2949-3003.
[http://dx.doi.org/10.1093/eurheartj/eht296] [PMID: 23996286]
[7]
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893-962.
[http://dx.doi.org/10.1093/eurheartj/ehw210] [PMID: 27567408]
[8]
Gurbel PA, Tantry US. Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. JACC Heart Fail 2014; 2(1): 1-14.
[http://dx.doi.org/10.1016/j.jchf.2013.07.007] [PMID: 24622113]
[9]
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128(16): 1810-52.
[http://dx.doi.org/10.1161/CIR.0b013e31829e8807] [PMID: 23741057]
[10]
Lip GY, Ponikowski P, Andreotti F, et al. ESC Task Force. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail 2012; 14(7): 681-95.
[http://dx.doi.org/10.1093/eurjhf/hfs073] [PMID: 22611046]
[11]
Kim W, Kim EJ. Heart Failure as a Risk Factor for Stroke. J Stroke 2018; 20(1): 33-45.
[http://dx.doi.org/10.5853/jos.2017.02810] [PMID: 29402070]
[12]
Lowe GD. Virchow’s triad revisited: abnormal flow. Pathophysiol Haemost Thromb 2003; 33(5-6): 455-7.
[http://dx.doi.org/10.1159/000083845] [PMID: 15692260]
[13]
O’Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999; 83(9): 1345-9.
[http://dx.doi.org/10.1016/S0002-9149(99)00098-3] [PMID: 10235093]
[14]
Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993; 14(2): 205-12.
[http://dx.doi.org/10.1093/eurheartj/14.2.205] [PMID: 8449196]
[15]
Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127(3): 607-12.
[http://dx.doi.org/10.1016/0002-8703(94)90670-X] [PMID: 8122609]
[16]
Serebruany VL, Murugesan SR, Pothula A, et al. Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. Eur J Heart Fail 1999; 1(3): 243-9.
[http://dx.doi.org/10.1016/S1388-9842(99)00029-X] [PMID: 10935670]
[17]
Stumpf C, Lehner C, Eskafi S, et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003; 5(5): 629-37.
[http://dx.doi.org/10.1016/S1388-9842(03)00110-7] [PMID: 14607202]
[18]
Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995; 25(7): 1634-40.
[http://dx.doi.org/10.1016/0735-1097(95)00049-A] [PMID: 7539015]
[19]
Jug B, Vene N, Salobir BG, Sebestjen M, Sabovic M, Keber I. Procoagulant state in heart failure with preserved left ventricular ejection fraction. Int Heart J 2009; 50(5): 591-600.
[http://dx.doi.org/10.1536/ihj.50.591] [PMID: 19809208]
[20]
Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis 2003; 14(6): 515-21.
[http://dx.doi.org/10.1097/00001721-200309000-00001] [PMID: 12960603]
[21]
Cugno M, Mari D, Meroni PL, et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. Br J Haematol 2004; 126(1): 85-92.
[http://dx.doi.org/10.1111/j.1365-2141.2004.04977.x] [PMID: 15198737]
[22]
Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103(13): 1746-51.
[http://dx.doi.org/10.1161/01.CIR.103.13.1746] [PMID: 11282905]
[23]
Alehagen U, Dahlström U, Lindahl TL. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 2004; 92(6): 1250-8.
[PMID: 15583730]
[24]
Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323(4): 236-41.
[http://dx.doi.org/10.1056/NEJM199007263230405] [PMID: 2195340]
[25]
Chong AY, Lip GY. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response? Eur J Heart Fail 2007; 9(2): 124-8.
[http://dx.doi.org/10.1016/j.ejheart.2006.05.009] [PMID: 16859990]
[26]
Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95(3): 995-1001.
[http://dx.doi.org/10.1172/JCI117809] [PMID: 7884001]
[27]
Preckel D, von Känel R. Regulation of Hemostasis by the Sympathetic Nervous System: Any Contribution to Coronary Artery Disease? HeartDrug 2004; 4(3): 123-30.
[http://dx.doi.org/10.1159/000078415] [PMID: 19169370]
[28]
Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84(4): 1589-96.
[http://dx.doi.org/10.1161/01.CIR.84.4.1589] [PMID: 1914099]
[29]
Bank AJ, Lee PC, Kubo SH. Endothelial dysfunction in patients with heart failure: relationship to disease severity. J Card Fail 2000; 6(1): 29-36.
[http://dx.doi.org/10.1016/S1071-9164(00)00009-9] [PMID: 10746816]
[30]
Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004; 110(13): 1794-8.
[http://dx.doi.org/10.1161/01.CIR.0000143073.60937.50] [PMID: 15364797]
[31]
Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol 2012; 60(16): 1455-69.
[http://dx.doi.org/10.1016/j.jacc.2011.11.082] [PMID: 22999723]
[32]
Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow’s triad revisited. J Am Coll Cardiol 1999; 33(5): 1424-6.
[PMID: 10193748]
[33]
Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in Heart Failure: Still Relevant? JACC Heart Fail 2018; 6(3): 201-8.
[http://dx.doi.org/10.1016/j.jchf.2017.08.023] [PMID: 29128254]
[34]
Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31(15): 1872-80.
[http://dx.doi.org/10.1093/eurheartj/ehq158] [PMID: 20570952]
[35]
Franchini M, Targher G, Montagnana M, Lippi G. Iron and thrombosis. Ann Hematol 2008; 87(3): 167-73.
[http://dx.doi.org/10.1007/s00277-007-0416-1] [PMID: 18066546]
[36]
Besarab A, Hörl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist 2009; 14(Suppl. 1): 22-33.
[http://dx.doi.org/10.1634/theoncologist.2009-S1-22] [PMID: 19762514]
[37]
Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke 2003; 34(1): 122-6.
[http://dx.doi.org/10.1161/01.STR.0000047852.05842.3C] [PMID: 12511762]
[38]
Witt BJ, Brown RD Jr, Jacobsen SJ, et al. Ischemic stroke after heart failure: a community-based study. Am Heart J 2006; 152(1): 102-9.
[http://dx.doi.org/10.1016/j.ahj.2005.10.018] [PMID: 16824838]
[39]
Alberts VP, Bos MJ, Koudstaal P, et al. Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol 2010; 25(11): 807-12.
[http://dx.doi.org/10.1007/s10654-010-9520-y] [PMID: 21061046]
[40]
Fang MC, Coca Perraillon M, Ghosh K, Cutler DM, Rosen AB. Trends in stroke rates, risk, and outcomes in the United States, 1988 to 2008. Am J Med 2014; 127(7): 608-15.
[http://dx.doi.org/10.1016/j.amjmed.2014.03.017] [PMID: 24680794]
[41]
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429-35.
[http://dx.doi.org/10.1056/NEJM198706043162301] [PMID: 2883575]
[42]
Witt BJ, Gami AS, Ballman KV, et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 2007; 13(6): 489-96.
[http://dx.doi.org/10.1016/j.cardfail.2007.01.009] [PMID: 17675064]
[43]
Adelborg K, Szépligeti S, Sundbøll J, et al. Risk of Stroke in Patients With Heart Failure: A Population-Based 30-Year Cohort Study. Stroke 2017; 48(5): 1161-8.
[http://dx.doi.org/10.1161/STROKEAHA.116.016022] [PMID: 28377383]
[44]
Freudenberger RS, Hellkamp AS, Halperin JL, et al. SCD-HeFT Investigators. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2007; 115(20): 2637-41.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.661397] [PMID: 17485579]
[45]
Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997; 29(5): 1074-80.
[http://dx.doi.org/10.1016/S0735-1097(97)00019-3] [PMID: 9120162]
[46]
Hays AG, Sacco RL, Rundek T, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 2006; 37(7): 1715-9.
[http://dx.doi.org/10.1161/01.STR.0000227121.34717.40] [PMID: 16741172]
[47]
Abdul-Rahim AH, Perez AC, Fulton RL, et al. Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials. Circulation 2015; 131(17): 1486-94.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013760] [PMID: 25810334]
[48]
Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336(4): 251-7.
[http://dx.doi.org/10.1056/NEJM199701233360403] [PMID: 8995087]
[49]
Sampson UK, Pfeffer MA, McMurray JJ, Lokhnygina Y, White HD, Solomon SD. VALIANT Trial Investigators. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. Eur Heart J 2007; 28(6): 685-91.
[http://dx.doi.org/10.1093/eurheartj/ehl197] [PMID: 16984929]
[50]
Abdul-Rahim AH, Perez AC, MacIsaac RL, et al. Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved (CHARM-Preserved) and the Irbesartan in Heart Failure with Preserved Systolic Function (I-Preserve) Steering Committees. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J 2017; 38(10): 742-50.
[PMID: 28426886]
[51]
Cogswell RJ, Norby FL, Gottesman RF, et al. High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction. Eur J Heart Fail 2017; 19(10): 1303-9.
[http://dx.doi.org/10.1002/ejhf.812] [PMID: 28738140]
[52]
Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1): 11-21.
[http://dx.doi.org/10.1056/NEJMoa1009492] [PMID: 21073363]
[53]
Tavazzi L, Maggioni AP, Marchioli R, et al. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9645): 1231-9.
[http://dx.doi.org/10.1016/S0140-6736(08)61240-4] [PMID: 18757089]
[54]
Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357(22): 2248-61.
[http://dx.doi.org/10.1056/NEJMoa0706201] [PMID: 17984166]
[55]
Zannad F, Anker SD, Byra WM, et al. COMMANDER HF Investigators. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med 2018; 379(14): 1332-42.
[http://dx.doi.org/10.1056/NEJMoa1808848] [PMID: 30146935]
[56]
Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102(6): 611-6.
[http://dx.doi.org/10.1161/01.CIR.102.6.611] [PMID: 10931799]
[57]
Sørensen HT, Horvath-Puho E, Lash TL, et al. Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation 2011; 124(13): 1435-41.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.025627] [PMID: 21900083]
[58]
Beemath A, Stein PD, Skaf E, Al Sibae MR, Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol 2006; 98(6): 793-5.
[http://dx.doi.org/10.1016/j.amjcard.2006.03.064] [PMID: 16950187]
[59]
Prandoni P, Pesavento R, Sørensen HT, et al. Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey. Eur J Intern Med 2009; 20(5): 470-3.
[http://dx.doi.org/10.1016/j.ejim.2009.06.001] [PMID: 19712846]
[60]
Dean SM, Abraham W. Venous thromboembolic disease in congestive heart failure. Congest Heart Fail 2010; 16(4): 164-9.
[http://dx.doi.org/10.1111/j.1751-7133.2010.00148.x] [PMID: 20662869]
[61]
Tang L, Wu YY, Lip GY, Yin P, Hu Y. Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol 2016; 3(1): e30-44.
[http://dx.doi.org/10.1016/S2352-3026(15)00228-8] [PMID: 26765646]
[62]
Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107(23): 2920-5.
[http://dx.doi.org/10.1161/01.CIR.0000072767.89944.6E] [PMID: 12771006]
[63]
Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293-302.
[http://dx.doi.org/10.1056/NEJM199108013250501] [PMID: 2057034]
[64]
Lubitz SA, Benjamin EJ, Ellinor PT. Atrial fibrillation in congestive heart failure. Heart Fail Clin 2010; 6(2): 187-200.
[http://dx.doi.org/10.1016/j.hfc.2009.11.001] [PMID: 20347787]
[65]
De Ferrari GM, Klersy C, Ferrero P, et al. ALPHA Study Group. Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail 2007; 9(5): 502-9.
[http://dx.doi.org/10.1016/j.ejheart.2006.10.021] [PMID: 17174599]
[66]
Santhanakrishnan R, Wang N, Larson MG, et al. Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation 2016; 133(5): 484-92.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.018614] [PMID: 26746177]
[67]
Pandey A, Kim S, Moore C, et al. ORBIT-AF Investigators and Patients. Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. JACC Heart Fail 2017; 5(1): 44-52.
[http://dx.doi.org/10.1016/j.jchf.2016.09.016] [PMID: 28034376]
[68]
Rosenberg MA, Manning WJ. Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circulation 2012; 126(19): 2353-62.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.113233] [PMID: 23129702]
[69]
Lip GY, Heinzel FR, Gaita F, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Eur J Heart Fail 2015; 17(9): 848-74.
[http://dx.doi.org/10.1002/ejhf.338] [PMID: 26293171]
[70]
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22(8): 983-8.
[http://dx.doi.org/10.1161/01.STR.22.8.983] [PMID: 1866765]
[71]
McManus DD, Hsu G, Sung SH, et al. Cardiovascular Research Network PRESERVE Study. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc 2013; 2(1)e005694
[http://dx.doi.org/10.1161/JAHA.112.005694] [PMID: 23525446]
[72]
Olsson LG, Swedberg K, Ducharme A, et al. CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 47(10): 1997-2004.
[http://dx.doi.org/10.1016/j.jacc.2006.01.060] [PMID: 16697316]
[73]
Banerjee A, Taillandier S, Olesen JB, et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail 2012; 14(3): 295-301.
[http://dx.doi.org/10.1093/eurjhf/hfs005] [PMID: 22294759]
[74]
Badheka AO, Rathod A, Kizilbash MA, et al. Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction. Am J Cardiol 2011; 108(9): 1283-8.
[http://dx.doi.org/10.1016/j.amjcard.2011.06.045] [PMID: 21855829]
[75]
Kotecha D, Banerjee A, Lip GY. Increased stroke risk in atrial fibrillation patients with heart failure: does ejection fraction matter? Stroke 2015; 46(3): 608-9.
[http://dx.doi.org/10.1161/STROKEAHA.114.008421] [PMID: 25628305]
[76]
Vemmos K, Ntaios G, Savvari P, et al. Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. Eur J Heart Fail 2012; 14(2): 211-8.
[http://dx.doi.org/10.1093/eurjhf/hfr172] [PMID: 22200911]
[77]
Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study. J Stroke Cerebrovasc Dis 1995; 5(3): 147-57.
[http://dx.doi.org/10.1016/S1052-3057(10)80166-1] [PMID: 26486811]
[78]
Kang SH, Kim J, Park JJ, et al. Risk of stroke in congestive heart failure with and without atrial fibrillation. Int J Cardiol 2017; 248: 182-7.
[http://dx.doi.org/10.1016/j.ijcard.2017.07.056] [PMID: 28826798]
[79]
Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158(12): 1316-20.
[http://dx.doi.org/10.1001/archinte.158.12.1316] [PMID: 9645825]
[80]
Agarwal M, Apostolakis S, Lane DA, Lip GY. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther 2014; 36(9): 1135-44.
[http://dx.doi.org/10.1016/j.clinthera.2014.07.015] [PMID: 25146364]
[81]
Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849-60.
[http://dx.doi.org/10.1016/S0140-6736(09)60503-1] [PMID: 19482214]
[82]
Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31(2): 419-25.
[http://dx.doi.org/10.1016/S0735-1097(97)00502-0] [PMID: 9462588]
[83]
Masoudi FA, Wolfe P, Havranek EP, Rathore SS, Foody JM, Krumholz HM. Aspirin use in older patients with heart failure and coronary artery disease: national prescription patterns and relationship with outcomes. J Am Coll Cardiol 2005; 46(6): 955-62.
[http://dx.doi.org/10.1016/j.jacc.2004.07.062] [PMID: 16168275]
[84]
Bermingham M, Shanahan MK, O’Connell E, et al. Aspirin use in heart failure: is low-dose therapy associated with mortality and morbidity benefits in a large community population? Circ Heart Fail 2014; 7(2): 243-50.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000132] [PMID: 24493706]
[85]
Lip GY, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst Rev 2001; (4): CD003333
[PMID: 11687189]
[86]
Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148(1): 157-64.
[http://dx.doi.org/10.1016/j.ahj.2004.03.010] [PMID: 15215806]
[87]
Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK. HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006; 8(4): 428-32.
[http://dx.doi.org/10.1016/j.ejheart.2006.02.012] [PMID: 16737850]
[88]
Massie BM, Collins JF, Ammon SE, et al. WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119(12): 1616-24.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.801753] [PMID: 19289640]
[89]
Homma S, Thompson JL, Pullicino PM, et al. WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366(20): 1859-69.
[http://dx.doi.org/10.1056/NEJMoa1202299] [PMID: 22551105]
[90]
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12): 857-67.
[http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00007] [PMID: 17577005]
[91]
Massie BM. Aspirin use in chronic heart failure: what should we recommend to the practitioner? J Am Coll Cardiol 2005; 46(6): 963-6.
[http://dx.doi.org/10.1016/j.jacc.2004.10.082] [PMID: 16168276]
[92]
Ahmed A. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure? J Am Geriatr Soc 2002; 50(7): 1293-6.
[http://dx.doi.org/10.1046/j.1532-5415.2002.50320.x] [PMID: 12133028]
[93]
Brunner-La Rocca HP. Interaction of angiotensin-converting enzyme inhibition and aspirin in congestive heart failure: long controversy finally resolved? Chest 2003; 124(4): 1192-4.
[http://dx.doi.org/10.1378/chest.124.4.1192] [PMID: 14555544]
[94]
Barbash IM, Goldbourt U, Gottlieb S, Behar S, Leor J. Possible interaction between aspirin and ACE inhibitors: update on unresolved controversy. Congest Heart Fail 2000; 6(6): 313-8.
[http://dx.doi.org/10.1111/j.1527-5299.2000.80174.x] [PMID: 12189336]
[95]
Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79(2): 115-9.
[http://dx.doi.org/10.1016/S0002-9149(96)00696-0] [PMID: 9193008]
[96]
McAlister FA, Ghali WA, Gong Y, Fang J, Armstrong PW, Tu JV. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation 2006; 113(22): 2572-8.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.602136] [PMID: 16735672]
[97]
Teo KK, Yusuf S, Pfeffer M, et al. ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360(9339): 1037-43.
[http://dx.doi.org/10.1016/S0140-6736(02)11138-X] [PMID: 12383982]
[98]
Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46(1): 27-31.
[http://dx.doi.org/10.1136/gut.46.1.27] [PMID: 10601050]
[99]
Madelaire C, Gislason G, Kristensen SL, et al. Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation: A Nationwide Propensity-Matched Study. JACC Heart Fail 2018; 6(2): 156-67.
[http://dx.doi.org/10.1016/j.jchf.2017.09.021] [PMID: 29413372]
[100]
Chin KL, Collier TJ, Pitt B, et al. EMPHASIS-HF Study Investigators. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. Eur J Heart Fail 2016; 18(9): 1175-81.
[http://dx.doi.org/10.1002/ejhf.485] [PMID: 26833642]
[101]
Cleland JGF. Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! Eur J Heart Fail 2017; 19(9): 1086-8.
[http://dx.doi.org/10.1002/ejhf.697] [PMID: 27943554]
[102]
Kozdağ G, Yaymacı M, Ertaş G, et al. Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure. Heart Vessels 2012; 27(6): 568-75.
[http://dx.doi.org/10.1007/s00380-011-0185-6] [PMID: 21909806]
[103]
Bonde L, Sorensen R, Fosbøl EL, et al. Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study. J Am Coll Cardiol 2010; 55(13): 1300-7.
[http://dx.doi.org/10.1016/j.jacc.2009.11.057] [PMID: 20338489]
[104]
Camm AJ, Kirchhof P, Lip GY, et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery.. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31(19): 2369-429.
[http://dx.doi.org/10.1093/eurheartj/ehq278] [PMID: 20802247]
[105]
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112(12): e154-235.
[PMID: 16160202]
[106]
Lindenfeld J, Albert NM, Boehmer JP, et al. Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16(6): e1-e194.
[http://dx.doi.org/10.1016/j.cardfail.2010.04.004] [PMID: 20610207]
[107]
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10(10): 933-89.
[http://dx.doi.org/10.1016/j.ejheart.2008.08.005] [PMID: 18826876]
[108]
Griffith GC, Stragnell R, Levinson DC, Moore FJ, Ware AG. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med 1952; 37(5): 867-87.
[http://dx.doi.org/10.7326/0003-4819-37-5-867] [PMID: 12986600]
[109]
Harvey WP, Finch CA. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med 1950; 242(6): 208-11.
[http://dx.doi.org/10.1056/NEJM195002092420603] [PMID: 15403339]
[110]
Anderson GM, Hull E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J 1950; 39(5): 697-702.
[http://dx.doi.org/10.1016/0002-8703(50)90129-3] [PMID: 15413578]
[111]
Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 31(4): 749-53.
[http://dx.doi.org/10.1016/S0735-1097(98)00006-0] [PMID: 9525542]
[112]
Lip GY, Rasmussen LH, Skjøth F, Overvad K, Larsen TB. Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. BMJ Open 2012; 2(4)e000975
[http://dx.doi.org/10.1136/bmjopen-2012-000975] [PMID: 22773537]
[113]
Mujib M, Rahman AA, Desai RV, et al. Warfarin use and outcomes in patients with advanced chronic systolic heart failure without atrial fibrillation, prior thromboembolic events, or prosthetic valves. Am J Cardiol 2011; 107(4): 552-7.
[http://dx.doi.org/10.1016/j.amjcard.2010.10.012] [PMID: 21185004]
[114]
Avellana P, Segovia J, Ferrero A. etalAnticoagulation therapy in patients with heart failure due to systolic dysfunction and sinusrhythm: analysis of REDINSCOR registry.. Rev Esp Cardiol (Engl Ed) 2012; 65(8): 705--12.
[http://dx.doi.org/10.1016/j.rec.2011.11.016] [PMID: 22464104]
[115]
Homma S, Thompson JL, Sanford AR, et al. WARCEF Investigators. Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial. Circ Heart Fail 2013; 6(5): 988-97.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000372] [PMID: 23881846]
[116]
Hopper I, Skiba M, Krum H. Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm. Eur J Heart Fail 2013; 15(1): 69-78.
[http://dx.doi.org/10.1093/eurjhf/hfs171] [PMID: 23143796]
[117]
Liew AY, Eikelboom JW, Connolly SJ, O’ Donnell M, Hart RG. Efficacy and safety of warfarin vs. antiplatelet therapy in patients with systolic heart failure and sinus rhythm: a systematic review and meta-analysis of randomized controlled trials. Int J Stroke 2014; 9(2): 199-206.
[http://dx.doi.org/10.1111/ijs.12036] [PMID: 23506160]
[118]
Maleki M, Vakilian F, Amin A. Liver diseases in heart failure. Heart Asia 2011; 3(1): 143-9.
[PMID: 27326014]
[119]
Brown LAE, Boos CJ. Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant. Int J Cardiol 2017; 227: 863-8.
[http://dx.doi.org/10.1016/j.ijcard.2016.09.086] [PMID: 28029411]
[120]
Savarese G, Giugliano RP, Rosano GM, et al. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. JACC Heart Fail 2016; 4(11): 870-80.
[http://dx.doi.org/10.1016/j.jchf.2016.07.012] [PMID: 27614940]
[121]
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39(2): 119-77.
[http://dx.doi.org/10.1093/eurheartj/ehx393] [PMID: 28886621]
[122]
Habash F, Vallurupalli S. Challenges in management of left ventricular thrombus. Ther Adv Cardiovasc Dis 2017; 11(8): 203-13.
[http://dx.doi.org/10.1177/1753944717711139] [PMID: 28589748]
[123]
Stratton JR, Resnick AD. Increased embolic risk in patients with left ventricular thrombi. Circulation 1987; 75(5): 1004-11.
[http://dx.doi.org/10.1161/01.CIR.75.5.1004] [PMID: 3568301]
[124]
Lee JM, Park JJ, Jung HW, et al. Left ventricular thrombus and subsequent thromboembolism, comparison of anticoagulation, surgical removal, and antiplatelet agents. J Atheroscler Thromb 2013; 20(1): 73-93.
[http://dx.doi.org/10.5551/jat.13540] [PMID: 22986555]
[125]
Johannessen KA, Nordrehaug JE, von der Lippe G. Left ventricular thrombi after short-term high-dose anticoagulants in acute myocardial infarction. Eur Heart J 1987; 8(9): 975-80.
[http://dx.doi.org/10.1093/oxfordjournals.eurheartj.a062374] [PMID: 3665957]
[126]
Stratton JR, Nemanich JW, Johannessen KA, Resnick AD. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. Circulation 1988; 78(6): 1388-93.
[http://dx.doi.org/10.1161/01.CIR.78.6.1388] [PMID: 3191593]
[127]
Ebrahimi M, Fazlinezhad A, Alvandi-Azari M, Abdar Esfahani M. Long-term clinical outcomes of the left ventricular thrombus in patients with ST elevation anterior myocardial infarction. ARYA Atheroscler 2015; 11(1): 1-4.
[PMID: 26089924]
[128]
Weinreich DJ, Burke JF, Pauletto FJ. Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography. Ann Intern Med 1984; 100(6): 789-94.
[http://dx.doi.org/10.7326/0003-4819-100-6-789] [PMID: 6721297]
[129]
Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol 2000; 86(12B): 48M-52M.
[http://dx.doi.org/10.1016/S0002-9149(00)01481-8] [PMID: 11206019]
[130]
Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14(4): 341-6.
[http://dx.doi.org/10.1097/00001721-200306000-00004] [PMID: 12945875]
[131]
Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW. THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003; 145(4): 614-21.
[http://dx.doi.org/10.1067/mhj.2003.189] [PMID: 12679756]
[132]
Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146(4): 278-88.
[http://dx.doi.org/10.7326/0003-4819-146-4-200702200-00007] [PMID: 17310052]
[133]
Cohen AT, Davidson BL, Gallus AS, et al. ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332(7537): 325-9.
[http://dx.doi.org/10.1136/bmj.38733.466748.7C] [PMID: 16439370]
[134]
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36(41): 2793-867.
[http://dx.doi.org/10.1093/eurheartj/ehv316] [PMID: 26320108]
[135]
Deshmukh A, Brown ML, Higgins E, et al. Performance of Atrial Fibrillation Detection in a New Single-Chamber ICD. Pacing Clin Electrophysiol 2016; 39(10): 1031-7.
[http://dx.doi.org/10.1111/pace.12918] [PMID: 27433785]
[136]
Healey JS, Connolly SJ, Gold MR, et al. ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366(2): 120-9.
[http://dx.doi.org/10.1056/NEJMoa1105575] [PMID: 22236222]
[137]
Hindricks G, Pokushalov E, Urban L, et al. XPECT Trial Investigators. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: Results of the XPECT trial. Circ Arrhythm Electrophysiol 2010; 3(2): 141-7.
[http://dx.doi.org/10.1161/CIRCEP.109.877852] [PMID: 20160169]
[138]
Gorenek B, Bax J, Boriani G, et al. ESC Scientific Document Group. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 2017; 19(9): 1556-78.
[http://dx.doi.org/10.1093/europace/eux163] [PMID: 28934408]
[139]
Glotzer TV, Hellkamp AS, Zimmerman J, et al. MOST Investigators. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003; 107(12): 1614-9.
[http://dx.doi.org/10.1161/01.CIR.0000057981.70380.45] [PMID: 12668495]
[140]
Miyazawa K, Pastori D, Li YG, et al. Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes. Clin Res Cardiol 2019; 108(9): 1034-41.
[http://dx.doi.org/10.1007/s00392-019-01432-y] [PMID: 30759274]
[141]
Bertaglia E, Blank B, Blomström-Lundqvist C, et al. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace 2019; 21(10): 1459-67.
[http://dx.doi.org/10.1093/europace/euz172] [PMID: 31377792]
[142]
Van Gelder IC, Healey JS, Crijns HJGM, et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2017; 38(17): 1339-44.
[http://dx.doi.org/10.1093/eurheartj/ehx042] [PMID: 28329139]
[143]
Nakano M, Kondo Y, Nakano M, et al. Impact of atrial high-rate episodes on the risk of future stroke. J Cardiol 2019; 74(2): 144-9.
[http://dx.doi.org/10.1016/j.jjcc.2019.01.006] [PMID: 30728105]
[144]
Lopes RD, Alings M, Connolly SJ, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J 2017; 189: 137-45.
[http://dx.doi.org/10.1016/j.ahj.2017.04.008] [PMID: 28625370]
[145]
Kirchhof P, Blank BF, Calvert M, et al. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J 2017; 190: 12-8.
[http://dx.doi.org/10.1016/j.ahj.2017.04.015] [PMID: 28760205]
[146]
Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag 2015; 11: 967-77.
[http://dx.doi.org/10.2147/TCRM.S84210] [PMID: 26150723]
[147]
Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15(3): 244-52.
[http://dx.doi.org/10.18553/jmcp.2009.15.3.244] [PMID: 19326955]
[148]
Witt DM, Delate T, Clark NP, et al. Warfarin Associated Research Projects and other EnDeavors (WARPED) Consortium. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 2009; 114(5): 952-6.
[http://dx.doi.org/10.1182/blood-2009-02-207928] [PMID: 19439733]
[149]
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57(2): 173-80.
[http://dx.doi.org/10.1016/j.jacc.2010.09.024] [PMID: 21111555]
[150]
White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167(3): 239-45.
[http://dx.doi.org/10.1001/archinte.167.3.239] [PMID: 17296878]
[151]
Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106(5): 968-77.
[http://dx.doi.org/10.1160/TH11-05-0353] [PMID: 21901239]
[152]
Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51.
[http://dx.doi.org/10.1056/NEJMoa0905561] [PMID: 19717844]
[153]
Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
[http://dx.doi.org/10.1056/NEJMoa1009638] [PMID: 21830957]
[154]
Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.
[http://dx.doi.org/10.1056/NEJMoa1107039] [PMID: 21870978]
[155]
Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093-104.
[http://dx.doi.org/10.1056/NEJMoa1310907] [PMID: 24251359]
[156]
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383(9921): 955-62.
[http://dx.doi.org/10.1016/S0140-6736(13)62343-0] [PMID: 24315724]
[157]
Ferreira J, Ezekowitz MD, Connolly SJ, et al. RE-LY Investigators. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 2013; 15(9): 1053-61.
[http://dx.doi.org/10.1093/eurjhf/hft111] [PMID: 23843099]
[158]
van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013; 6(4): 740-7.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000212] [PMID: 23723250]
[159]
McMurray JJ, Ezekowitz JA, Lewis BS, et al. ARISTOTLE Committees and Investigators. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 2013; 6(3): 451-60.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.000143] [PMID: 23575255]
[160]
Magnani G, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail 2016; 18(9): 1153-61.
[http://dx.doi.org/10.1002/ejhf.595] [PMID: 27349698]
[161]
Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015; 17(11): 1192-200.
[http://dx.doi.org/10.1002/ejhf.343] [PMID: 26335355]
[162]
Steffel J, Verhamme P, Potpara TS, et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39(16): 1330-93.
[http://dx.doi.org/10.1093/eurheartj/ehy136] [PMID: 29562325]
[163]
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17(10): 1467-507.
[http://dx.doi.org/10.1093/europace/euv309] [PMID: 26324838]
[164]
Hylek EM. Apixaban for End-Stage Kidney Disease. Circulation 2018; 138(15): 1534-6.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036449] [PMID: 30354524]
[165]
Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366(1): 9-19.
[http://dx.doi.org/10.1056/NEJMoa1112277] [PMID: 22077192]
[166]
Korjian S, Braunwald E, Daaboul Y, et al. Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). Am J Cardiol 2018; 122(11): 1896-901.
[http://dx.doi.org/10.1016/j.amjcard.2018.08.034] [PMID: 30340765]
[167]
Branch KR, Probstfield JL, Eikelboom JW, et al. Rivaroxaban With or Without Aspirin in Patients with Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial. Circulation 2019. [Epub ahead of print].
[168]
Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377(14): 1319-30.
[http://dx.doi.org/10.1056/NEJMoa1709118] [PMID: 28844192]
[169]
Cornel JH, Lopes RD, James S, et al. APPRAISE-2 Study Group. Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. Am Heart J 2015; 169(4): 531-8.
[http://dx.doi.org/10.1016/j.ahj.2014.12.022] [PMID: 25819860]
[170]
Alexander JH, Lopes RD, James S, et al. APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365(8): 699-708.
[http://dx.doi.org/10.1056/NEJMoa1105819] [PMID: 21780946]
[171]
Kajy M, Shokr M, Ramappa P. Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: Systematic Review of Current Literature. Am J Ther 2019. Epub ahead of print
[http://dx.doi.org/10.1097/MJT.0000000000000937] [PMID: 30730331]
[172]
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285(22): 2864-70.
[http://dx.doi.org/10.1001/jama.285.22.2864] [PMID: 11401607]
[173]
Boos CJ, Nam M, Camm AJ. Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev 2014; 19(3): 391-401.
[http://dx.doi.org/10.1007/s10741-013-9398-3] [PMID: 23797696]
[174]
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137(2): 263-72.
[http://dx.doi.org/10.1378/chest.09-1584] [PMID: 19762550]
[175]
Ntaios G, Lip GY, Makaritsis K, et al. CHADS2, CHA2S2DS2-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology 2013; 80(11): 1009-17.
[http://dx.doi.org/10.1212/WNL.0b013e318287281b] [PMID: 23408865]
[176]
Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA 2015; 314(10): 1030-8.
[http://dx.doi.org/10.1001/jama.2015.10725] [PMID: 26318604]
[177]
Wolsk E, Lamberts M, Hansen ML, et al. Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a nationwide cohort study. Eur J Heart Fail 2015; 17(8): 828-36.
[http://dx.doi.org/10.1002/ejhf.309] [PMID: 26136386]
[178]
Freudenberger RS, Cheng B, Mann DL, et al. WARCEF Investigators. The first prognostic model for stroke and death in patients with systolic heart failure. J Cardiol 2016; 68(2): 100-3.
[http://dx.doi.org/10.1016/j.jjcc.2015.09.014] [PMID: 26549533]
[179]
Schumacher K, Kornej J, Shantsila E, Lip GYH. Heart Failure and Stroke. Curr Heart Fail Rep 2018; 15(5): 287-96.
[http://dx.doi.org/10.1007/s11897-018-0405-9] [PMID: 30062623]
[180]
Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113(11): 1424-33.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.584102] [PMID: 16534009]
[181]
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093-100.
[http://dx.doi.org/10.1378/chest.10-0134] [PMID: 20299623]
[182]
Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151(3): 713-9.
[http://dx.doi.org/10.1016/j.ahj.2005.04.017] [PMID: 16504638]
[183]
Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58(4): 395-401.
[http://dx.doi.org/10.1016/j.jacc.2011.03.031] [PMID: 21757117]
[184]
O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36(46): 3258-64.
[http://dx.doi.org/10.1093/eurheartj/ehv476] [PMID: 26424865]
[185]
Hijazi Z, Oldgren J, Lindbäck J, et al. ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387(10035): 2302-11.
[http://dx.doi.org/10.1016/S0140-6736(16)00741-8] [PMID: 27056738]
[186]
Baumgartner H, Falk V, Bax JJ, et al. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38(36): 2739-91.
[http://dx.doi.org/10.1093/eurheartj/ehx391] [PMID: 28886619]
[187]
Briasoulis A, Inampudi C, Akintoye E, Alvarez P, Panaich S, Vaughan-Sarrazin M. Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease. J Am Heart Assoc 2018; 7(8)e008773
[http://dx.doi.org/10.1161/JAHA.118.008773] [PMID: 29622591]
[188]
Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation 2015; 132(8): 624-32.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014807] [PMID: 26106009]
[189]
Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ 1964; 1(5392): 1209-12.
[http://dx.doi.org/10.1136/bmj.1.5392.1209] [PMID: 14120826]
[190]
Omran H, Rang B, Schmidt H, et al. Incidence of left atrial thrombi in patients in sinus rhythm and with a recent neurologic deficit. Am Heart J 2000; 140(4): 658-62.
[http://dx.doi.org/10.1067/mhj.2000.109213] [PMID: 11011342]
[191]
Black IW, Hopkins AP, Lee LC, Walsh WF. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol 1991; 18(2): 398-404.
[http://dx.doi.org/10.1016/0735-1097(91)90592-W] [PMID: 1856407]
[192]
Daniel WG, Nellessen U, Schröder E, et al. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol 1988; 11(6): 1204-11.
[http://dx.doi.org/10.1016/0735-1097(88)90283-5] [PMID: 2966840]
[193]
Gohlke-Bärwolf C, Acar J, Oakley C, et al. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Guidelines for prevention of thromboembolic events in valvular heart disease. Eur Heart J 1995; 16(10): 1320-30.
[http://dx.doi.org/10.1093/oxfordjournals.eurheartj.a060739] [PMID: 8746900]
[194]
Acartürk E, Usal A, Demir M, Akgül F, Ozeren A. Thromboembolism risk in patients with mitral stenosis. Jpn Heart J 1997; 38(5): 669-75.
[http://dx.doi.org/10.1536/ihj.38.669] [PMID: 9462416]
[195]
Olesen KH. The natural history of 271 patients with mitral stenosis under medical treatment. Br Heart J 1962; 24: 349-57.
[http://dx.doi.org/10.1136/hrt.24.3.349] [PMID: 14481743]
[196]
Galiè N, Humbert M, Vachiery JL, et al. ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37(1): 67-119.
[http://dx.doi.org/10.1093/eurheartj/ehv317] [PMID: 26320113]
[197]
Schölzel BE, Snijder RJ, Mager JJ, et al. Chronic thromboembolic pulmonary hypertension. Neth Heart J 2014; 22(12): 533-41.
[http://dx.doi.org/10.1007/s12471-014-0592-2] [PMID: 25169577]
[198]
Gavilanes-Oleas FA, Alves JL Jr, Fernandes CJC, et al. Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension. Clinics (São Paulo) 2018., 73e216
[http://dx.doi.org/10.6061/clinics/2018/e216] [PMID: 29791520]
[199]
Roldan T, Landzberg MJ, Deicicchi DJ, Atay JK, Waxman AB. Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge. J Heart Lung Transplant 2016; 35(2): 151-64.
[http://dx.doi.org/10.1016/j.healun.2015.10.002] [PMID: 26527532]
[200]
Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129(1): 57-65.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004526] [PMID: 24081973]
[201]
Preston IR, Roberts KE, Miller DP, et al. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation 2015; 132(25): 2403-11.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.018435] [PMID: 26510696]
[202]
Galie N, Delcroix M, Ghofrani A, et al. Anticoagulant therapy does not influence long-term outcomes in patients with pulmonary arterial hypertension (PAH): insights from the randomised controlled SERAPHIN trial of macitentan. Eur Heart J 2014; 35: 10.
[203]
Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112(3): 714-21.
[http://dx.doi.org/10.1378/chest.112.3.714] [PMID: 9315805]
[204]
Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005; 95(2): 199-203.
[http://dx.doi.org/10.1016/j.amjcard.2004.09.006] [PMID: 15642552]
[205]
Henkens IR, Hazenoot T, Boonstra A, Huisman MV, Vonk-Noordegraaf A. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J 2013; 41(4): 872-8.
[http://dx.doi.org/10.1183/09031936.00039212] [PMID: 22936704]
[206]
Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Hawker GA, Feldman BM. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. J Rheumatol 2011; 38(3): 462-9.
[http://dx.doi.org/10.3899/jrheum.100632] [PMID: 21159827]
[207]
Jensen AS, Idorn L, Nørager B, Vejlstrup N, Sondergaard L. Anticoagulation in adults with congenital heart disease: The who, the when and the how? Heart 2015; 101(6): 424-9.
[http://dx.doi.org/10.1136/heartjnl-2014-305576] [PMID: 25281599]
[208]
Feltes TF, Friedman RA. Transesophageal echocardiographic detection of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol 1994; 24(5): 1365-70.
[http://dx.doi.org/10.1016/0735-1097(94)90121-X] [PMID: 7930262]
[209]
Baumgartner H, Bonhoeffer P, De Groot NM, et al. . Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC); Association for European Paediatric Cardiology (AEPC); ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010).. Eur Heart J 2010; 31(23): 2915-57.
[http://dx.doi.org/10.1093/eurheartj/ehq249] [PMID: 20801927]
[210]
Silversides CK, Granton JT, Konen E, Hart MA, Webb GD, Therrien J. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003; 42(11): 1982-7.
[http://dx.doi.org/10.1016/j.jacc.2003.07.022] [PMID: 14662263]
[211]
Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007; 50(7): 634-42.
[http://dx.doi.org/10.1016/j.jacc.2007.04.056] [PMID: 17692749]
[212]
Sandoval J, Santos LE, Córdova J, et al. Does anticoagulation in Eisenmenger syndrome impact long-term survival? Congenit Heart Dis 2012; 7(3): 268-76.
[http://dx.doi.org/10.1111/j.1747-0803.2012.00633.x] [PMID: 22360787]
[213]
Yang H, Bouma BJ, Mulder BJM. Non vitamin K antagonist Oral anticoagulants for ThromboEmbolic prevention in adult congenital heart disease (NOTE) investigators. Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease? Cardiovasc Drugs Ther 2017; 31(4): 413-7.
[http://dx.doi.org/10.1007/s10557-017-6745-y] [PMID: 28785894]
[214]
Yang H, Veldtman GR, Bouma BJ, et al. Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe. Open Heart 2019; 6(1)e000985
[http://dx.doi.org/10.1136/openhrt-2018-000985] [PMID: 31245011]
[215]
Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8(8): 1308-39.
[http://dx.doi.org/10.1016/j.hrthm.2011.05.020] [PMID: 21787999]
[216]
Bennett CE, Freudenberger R. The Current Approach to Diagnosis and Management of Left Ventricular Noncompaction Cardiomyopathy: Review of the Literature. Cardiol Res Pract 2016; 20165172308
[http://dx.doi.org/10.1155/2016/5172308] [PMID: 26881173]
[217]
Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet 2015; 386(9995): 813-25.
[http://dx.doi.org/10.1016/S0140-6736(14)61282-4] [PMID: 25865865]
[218]
van Waning JI, Caliskan K, Hoedemaekers YM, et al. Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy. J Am Coll Cardiol 2018; 71(7): 711-22.
[http://dx.doi.org/10.1016/j.jacc.2017.12.019] [PMID: 29447731]
[219]
Greutmann M, Mah ML, Silversides CK, et al. Predictors of adverse outcome in adolescents and adults with isolated left ventricular noncompaction. Am J Cardiol 2012; 109(2): 276-81.
[http://dx.doi.org/10.1016/j.amjcard.2011.08.043] [PMID: 22036106]
[220]
Tavares de Melo MD, de Araújo Filho JA, Parga Filho JR, et al. Noncompaction cardiomyopathy: a substrate for a thromboembolic event. BMC Cardiovasc Disord 2015; 15: 7.
[http://dx.doi.org/10.1186/1471-2261-15-7] [PMID: 25618133]
[221]
Carrilho-Ferreira P, Almeida AG, Pinto FJ. Non-compaction cardiomyopathy: prevalence, prognosis, pathoetiology, genetics, and risk of cardioembolism. Curr Heart Fail Rep 2014; 11(4): 393-403.
[http://dx.doi.org/10.1007/s11897-014-0227-3] [PMID: 25239435]
[222]
Stöllberger C, Blazek G, Dobias C, Hanafin A, Wegner C, Finsterer J. Frequency of stroke and embolism in left ventricular hypertrabeculation/noncompaction. Am J Cardiol 2011; 108(7): 1021-3.
[http://dx.doi.org/10.1016/j.amjcard.2011.05.039] [PMID: 21784395]
[223]
Udeoji DU, Philip KJ, Morrissey RP, Phan A, Schwarz ER. Left ventricular noncompaction cardiomyopathy: updated review. Ther Adv Cardiovasc Dis 2013; 7(5): 260-73.
[http://dx.doi.org/10.1177/1753944713504639] [PMID: 24132556]
[224]
Habib G, Charron P, Eicher JC, et al. Working Groups ‘Heart Failure and Cardiomyopathies’ and ‘Echocardiography’ of the French Society of Cardiology. Isolated left ventricular non-compaction in adults: clinical and echocardiographic features in 105 patients. Results from a French registry. Eur J Heart Fail 2011; 13(2): 177-85.
[http://dx.doi.org/10.1093/eurjhf/hfq225] [PMID: 21193437]
[225]
Towbin JA, Jefferies JL. Cardiomyopathies Due to Left Ventricular Noncompaction, Mitochondrial and Storage Diseases, and Inborn Errors of Metabolism. Circ Res 2017; 121(7): 838-54.
[http://dx.doi.org/10.1161/CIRCRESAHA.117.310987] [PMID: 28912186]
[226]
Bocchi EA, Braga FG, Ferreira SM, et al. Sociedasde Brasileira de Cardiologia. [III Brazilian Guidelines on Chronic Heart Failure] Arq Bras Cardiol. 2009; 93(1)(Suppl. 1): 3-70.
[PMID: 20963312]
[227]
Fazio G, Corrado G, Zachara E, et al. Anticoagulant drugs in noncompaction: a mandatory therapy? J Cardiovasc Med (Hagerstown) 2008; 9(11): 1095-7.
[http://dx.doi.org/10.2459/JCM.0b013e328308da04] [PMID: 18852579]
[228]
Rosa LV, Salemi VM, Alexandre LM, Mady C. Noncompaction cardiomyopathy: a current view. Arq Bras Cardiol 2011; 97(1): e13-9.
[http://dx.doi.org/10.1590/S0066-782X2011000900021] [PMID: 21894393]
[229]
Floria M, Tinica G, Grecu M. Left ventricular non-compaction -challenges and controversies. Maedica (Buchar) 2014; 9(3): 282-8.
[PMID: 25705294]
[230]
Oechslin EN, Attenhofer Jost CH, Rojas JR, Kaufmann PA, Jenni R. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol 2000; 36(2): 493-500.
[http://dx.doi.org/10.1016/S0735-1097(00)00755-5] [PMID: 10933363]
[231]
Oechslin E, Jenni R. Left ventricular non-compaction revisited: a distinct phenotype with genetic heterogeneity? Eur Heart J 2011; 32(12): 1446-56.
[http://dx.doi.org/10.1093/eurheartj/ehq508] [PMID: 21285074]
[232]
Stöllberger C, Wegner C, Finsterer J. CHADS2- and CHA2DS2VASc scores and embolic risk in left ventricular hypertrabeculation/noncompaction. J Stroke Cerebrovasc Dis 2013; 22(6): 709-12.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2011.10.014] [PMID: 22142779]
[233]
Sun H, Zhao Q, Wang Y, et al. Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy: A case report. Medicine (Baltimore) 2018; 97(4) e9670
[http://dx.doi.org/10.1097/MD.0000000000009670] [PMID: 29369185]
[234]
Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res 2017; 121(7): 819-37.
[http://dx.doi.org/10.1161/CIRCRESAHA.117.310982] [PMID: 28912185]
[235]
Zhang XD, Liu YX, Yan XW, et al. Cerebral embolism secondary to cardiac amyloidosis: A case report and literature review. Exp Ther Med 2017; 14(6): 6077-83.
[http://dx.doi.org/10.3892/etm.2017.5301] [PMID: 29250142]
[236]
Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007; 116(21): 2420-6.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.697763] [PMID: 17984380]
[237]
Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009; 119(18): 2490-7.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.785014] [PMID: 19414641]
[238]
Yood RA, Skinner M, Rubinow A, Talarico L, Cohen AS. Bleeding manifestations in 100 patients with amyloidosis. JAMA 1983; 249(10): 1322-4.
[http://dx.doi.org/10.1001/jama.1983.03330340064034] [PMID: 6600795]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 23
Year: 2020
Published on: 14 July, 2020
Page: [2735 - 2761]
Pages: 27
DOI: 10.2174/1381612826666200531151823
Price: $65

Article Metrics

PDF: 31
HTML: 3